New insights into adipocyte-specific leptin gene expression

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Wrann, Christiane D., and Evan D. Rosen. 2012. New insights into adipocyte-specific leptin gene expression. Adipocyte 1(3): 168-172. |
|----------------|--------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.4161/adip.20574                                                                                                   |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:11357452                                                                       |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
New insights into adipocyte-specific leptin gene expression

Christiane D. Wrann1,2 and Evan D. Rosen1,3,*

1Division of Endocrinology, Diabetes, and Metabolism; Beth Israel Deaconess Medical Center; Boston, MA USA; 2Dana-Farber Cancer Institute and Department of Cell Biology; Harvard Medical School; Boston, MA USA; 3Broad Institute; Cambridge, MA USA

Keywords: leptin, Fosl2, transcription, obesity, diabetes, adipose, SILAC, ChIP-Seq

Submitted: 04/09/12
Revised: 04/30/12
Accepted: 04/30/12
http://dx.doi.org/10.4161/adip.20574

*Correspondence to: Evan D. Rosen;
Email: erosen@bidmc.harvard.edu

Introduction

Leptin is an adipocyte-derived hormone that regulates food intake and energy expenditure, acting primarily through the central nervous system.1,2 In addition to its well-established role in metabolism, leptin also affects physiological processes as wide-ranging as reproduction, thyroid function, bone density, and immune biology.3,4 Recombinant leptin has been developed as a drug for treating insulin resistance in patients with lipodystrophy.5 Although early studies using leptin as a weight loss agent in human obesity proved disappointing,6 recent trials using leptin in combination with the pancreatic polypeptide amylin show some promise.7 There has also been interest in using leptin to improve insulin action in a weight-loss independent fashion; however, recombinant methionyl human (r-Met hu) leptin did not enhance insulin sensitivity in obese subjects with type 2 diabetes.8 In the two decades since leptin was first identified, over 20,000 papers have been written describing leptin’s actions in physiology and pathophysiology. In stark contrast to the wealth of data regarding the functions of leptin, however, our knowledge about the mechanisms involved in the transcriptional regulation of leptin gene expression, particularly the basis for its adipocyte-specific expression, is rather limited. Leptin is regulated primarily at the transcriptional level, and a wide variety of physiological conditions and pharmacological agents have been shown to affect its expression, including fasting and feeding, insulin, glucocorticoids, thiazolidinediones and even leptin itself.9,10,11 These studies are summarized in Table 1.

Transcriptional Regulation of LEP Gene Expression

Leptin (encoded by the LEP gene in humans, Lep in mice) is generally expressed in an adipocyte-specific fashion. Small amounts of leptin have been reported in brain, pituitary, trophoblast, stomach, mammary epithelial cells, liver,
chondrocytes and muscle,\textsuperscript{4,12-14} but the physiological importance of this low level expression, if any, has not been determined.

The proximal promoters of the \textit{LEP} gene in mouse and human have been characterized\textsuperscript{15,16} and a classic TATA box has been identified, as well as binding sites for C/EBP, Sp-1, GR, and CREB, and an E box element that may bind SREBP1\textsubscript{c}.\textsuperscript{17-20} Although a transgenic reporter driven by a 762 bp leptin proximal promoter cassette was able to drive gene expression in vivo, it showed lower levels of expression in adipocytes than in a variety of non-adipose tissues and was not affected by fasting, suggesting that this region is not responsible for adipose tissue specificity of leptin expression or physiological regulation of leptin gene expression.\textsuperscript{21} Recently, the transcription factor activator protein-2\textsuperscript{β} (AP-2 \textsuperscript{β}) has been shown to inhibit \textit{LEP} expression by direct binding to the promoter.\textsuperscript{22} Various SNPs have been reported in the porcine leptin promoter that correlate with \textit{Lep} expression\textsuperscript{23,24} and demethylation of specific CpG islands occurs during adipogenesis, associated with the onset of \textit{Lep} expression\textsuperscript{25}.

All these studies have been limited by the fact that they have focused on the proximal promoter and/or on pre-specified adipocyte transcription factors. In fact, several major obstacles have impeded progress in identifying transcriptional pathways responsible for regulation of adipocyte-specific leptin gene expression, including (1) unreliable methods for unbiased detection of distal cis-regulatory elements, (2) insufficient tools to identify an unknown transcription factor binding to a known cis-regulatory element, and (3) a lack of good cell culture models for studying leptin gene expression in vitro. It is worth noting that the workhorse model of adipocyte research, the 3T3-L1 cell line, expresses extremely low levels of \textit{Lep}\textsuperscript{26} and is thus unsuitable for these studies. Recent advances in all of these areas encouraged us to pursue the mechanism of adipocyte-specific leptin gene expression once again.\textsuperscript{27}

### Identification of a cis-Regulatory Element for Adipocyte-Specific \textit{LEP} Gene Expression

We utilized a multi-step approach to finding cis-regulatory elements that direct \textit{lep} gene expression. First, we sought to map such regions grossly, using BAC-transgenic reporter mice that express EGFP from the \textit{Lep} translational start site. Analyzing multiple transgenic founders carrying BACs with varying lengths of \textit{Lep} flanking sequences allowed us to narrow down the region required for adipose-specific expression and demonstrated that the three \textit{Lep} exons, both introns, and 5.2 kb of 5' flanking sequence were sufficient to drive adipocyte-specific EGFP expression. Next, we performed fine-mapping in vitro, by “tiling” across the upstream flanking region and through both introns with PCR primers, to generate reporter constructs that we could test in cultured human adipocytes. These cells are derived from human adipose stromal cells (hASCs), which can be differentiated into mature adipocytes in vitro and produce high levels of leptin. This effort identified a single 1 kb region approximately 4.5 kb upstream of the \textit{LEP} transcriptional start site (TSS) that acts as enhancer in mature adipocytes. Further deletion and point mutations allowed us to discover a 30 bp region that was required for enhancer activity. Interestingly, we had previously performed chromatin state mapping in human adipocytes in culture, part of which involved mapping histone modifications associated with active and poised enhancers.\textsuperscript{28} The region we identified by reporter assays overlay an active enhancer region\textsuperscript{29,30} in our chromatin state maps (the only such place in the vicinity), which provided significant reassurance that we had identified a region of bona fide importance.

### Identification of the Transcription Factor(s) for Adipocyte-Specific \textit{LEP} Gene Expression

Once a relevant cis-regulatory element is found, it can be very difficult to identify the cognate transcription factor(s) that bind and activate it. The most common approach is to use computational motif finding to find sequences that suggest a particular factor. We tried this and found several interesting motifs for the androgen receptor (AR), peroxisome proliferator-activated receptor α (PPAR\textsubscript{α}) and nuclear factor erythroid 2-related factor 1 (NFE2L1). Unfortunately, functional

| Physiological conditions       | References | Direction of effect |
|-------------------------------|------------|---------------------|
| Fasting                       | 11, 26, 35 | ↓                   |
| Feeding                       | 11, 26, 35 | ↑                   |
| Obesity                       | 37         | ↑                   |
| Adipocyte volume              | 34         | ↑                   |

| Pharmacological agents         | References | Direction of effect |
|-------------------------------|------------|---------------------|
| Insulin                       | 26, 38, 39 | ↑                   |
| Glucose                       | 40         | ↑                   |
| Glucocorticoids               | 38, 39     | ↑                   |
| Hexosamines                   | 41-43      | ↑                   |
| Cytokines (TNF, IL-1 and LIF) and lipopolysaccharide (LPS) | 44, 45 | ↓ |
| β\textsubscript{3}-adrenergic agonist (CL316,243) | 35 | ↓ |
| Leptin                        | 46         | ↓                   |
| Thiazolidinediones (TZD)       | 10         | ↑                   |

| Transcription factors          | References | Direction of effect |
|-------------------------------|------------|---------------------|
| C/EBP\textsubscript{a}        | 17–19      | ↑                   |
| ADD1/SREBP\textsubscript{1}   | 20         | ↑                   |
| AP-2\textsubscript{β}         | 22         | ↓                   |
| FOSL2                         | 27         | ↑                   |
studies (i.e., overexpression and RNAi experiments) failed to demonstrate that any of these predicted factors were important in leptin expression. We therefore used our identified 30 bp cis-regulatory element as bait in an unbiased mass spectrometry-based quantitative proteomics approach combining stable isotope labeling by amino acids in cell culture (SILAC) with affinity enrichment of protein-DNA complexes using biotinylated DNA as affinity baits. To add specificity, we performed the assay in cultured human adipocytes as well as murine adipocytes differentiated from embryonic fibroblasts, both of which express leptin. Several transcription factors were found in each model, but Fosl2 and JUND were the only ones to appear in both. FOSL2 and JUND are both members of the AP1-transcription factor family, which includes FOS, FOSB, FOSL1, JUN, JUNB and JUND. We demonstrated that FOSL2 binds to our enhancer in mature human adipocytes, but not in precursors from Fosl2-transgenic mice showed higher Lep expression when differentiated into adipocytes in vitro. Since the Fosl2-transgenic mice suffered from systemic fibrosis and inflammation, metabolic studies of these animals could not be conducted. It appears that Fosl2 is both necessary and sufficient for leptin expression in adipocytes, but it must be present during the differentiation process to exert its effects. This implies that Fosl2 has both direct and indirect actions on the Lep gene.

Fasting and Feeding Regulation of Leptin Levels in Physiology and Pathophysiology

As mentioned above, apart from being expressed in adipocytes, Lep mRNA synthesis in adipocytes is regulated by a variety of physiological and experimental stimuli. In mice, there are depot-specific differences in Lep mRNA content, with inguinal fat expressing higher leptin levels than retroperitoneal or epididymal adipose tissue.9 There also appears to be a direct relationship between adipocyte volume and Lep expression regardless of depot.10 In our study, a correlation of increased levels of LEP gene expression with increased levels of FOSL2 gene expression was observed during the course of differentiation of human adipocytes and in different adipose depots in mice. In addition, we showed that stimulation of mature human adipocytes with dexamethasone resulted in increased LEP expression and simultaneous rise in FOSL2 expression.

Roles of FOSL2 in Regulating Leptin Levels in Obesity

To determine if Fosl2 plays a role in the elevated Lep expression observed in obesity, we analyzed Fosl2 expression in different mouse models of obesity. In mice with diet-induced obesity as well as in mice with genetic obesity (db/db), we found that increased Lep gene expression was accompanied by increased Fosl2 levels. A gene expression analysis of samples of subcutaneous fat from a human cohort with varying BMIs confirmed this association in humans.

Conclusions and Unanswered Questions

Several issues, however, remain unresolved. First of all, we do not yet understand how FOSL2, which is not tissue restricted to adipocytes, can regulate adipose-specific gene expression. There are several intriguing possible mechanisms, many of which are known to be employed by members of the AP-1 transcription factor family, to which FOSL2 belongs. These include differential expression, composition and orientation of the heterodimeric binding partners, post-translational modifications, and interaction with ancillary proteins.36 Interestingly, although we identified JUND as a potential binding partner on our 30 bp cis-regulatory element, we could not demonstrate a specific requirement for this or any other Jun isoform in Lep expression. Perhaps there is greater functional redundancy among the Jun proteins than between FOS, FOSL1 and FOSB, which apparently cannot compensate for the loss of FOSL2 in leptin expression. Other factors may also be acting in concert with FOSL2. For example, there is a bona fide PPARγ binding site at the 5′ end of the 1 kb cis-regulatory region we discovered. Perhaps PPARγ plays a role in enabling FOSL2 binding during adipogenesis.
Our results should by no means be taken to exclude a possible role for other cis-regulatory regions important for Lepr expression. Our BAC transgenic results suggest that multiple regions, especially at the 3’ end of the Lepr gene, may be involved as well. For example, truncation of the 3’ flanking sequence in our BAC transgenic reporter mouse model led to a significant decrease of EGFP expression in adipose tissue and increased EGFP expression in other tissues. Taken together, these data suggest that many genomic regions and transcription factors will eventually be shown to regulate leptin expression.

Our study provided one of the first clues into the transcriptional regulation of the medically important adipokine leptin. Despite the fact that leptin levels are primarily regulated at the transcriptional level, our understanding of the factors at play has been poorly developed. We utilized an integrated strategy that combined BAC transgenesis, human reporter assays, epigenomics, and unbiased quantitative proteomics to identify FOSL2. We believe that a similar multi-pronged approach will be required to tackle many of the remaining problems in tissue-specific transcriptional regulation.

References

1. Zhang Y, Preuncga R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-32; PMID:7984236; http://dx.doi.org/10.1038/372425a0
2. Halas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543-6; PMID:7624777; http://dx.doi.org/10.1126/science.7624777
3. Belgardt BF, Brüning JC. CNS leptin and insulin actions in the control of energy homeostasis. Ann N Y Acad Sci 2010; 1212:97-113; PMID:21070248; http://dx.doi.org/10.1111/j.1749-6632.2010.05799.x
4. Mariget S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26:1407-35; PMID:12439643; http://dx.doi.org/10.1038/sj.ijo.0801242
5. Friedman JM. Leptin at 14 y of age: an ongoing story. Am J Clin Nutr 2009; 89:973S-9; PMID:19190071; http://dx.doi.org/10.3945/ajcn.2008.26788B
6. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyazawa A, Takahashi Y, et al. Intraperitoneal injection of recombinant mouse leptin induces hyperleptinemia in diabetic mice. J Mol Endocrinol 2007; 38:537-46; PMID:17496155; http://dx.doi.org/10.1530/JME-06-0004
7. Moreno-Alagia MJ, Swarbrick MM, Lorente-Cebrián A, López-Maury L, Gallo P, Palau J, et al. Leptin concentrations in obese and lean subjects with type 2 diabetes. Diabetes 2011; 60:1474-7; PMID:21411512; http://dx.doi.org/10.2337/db10-1302
8. Gotoh H, Laigneau JP, Devaud H, Sobhani I, Bado T, Ugi S, et al. Transcription factor AP-2beta inhibits expression and secretion of leptin, an insulin-sensitizing hormone, in 3T3-L1 adipocytes. Int J Obesity (Lond) 2010; 34:6070-8; PMID:20869565; http://dx.doi.org/10.1038/ijo.2009.295
9. Stachowiak M, Mackowski M, Madeja Z, Sydlovský M, Buskova A, Kaczmarek P, et al. Polymorphism of the porcine leptin gene promoter and analysis of its association with gene expression and fattness traits. Biochem Genet 2007; 45:1731873; http://dx.doi.org/10.1007/s10528-006-9070-x
10. Liu D, Hu Y, Yang X, Liu Y, Wei S, Jiang Y. Identification and genetic effects of a novel polymorphism in the distal promoter region of porcine leptin gene. Mol Biol Rep 2011; 38:2051-7; PMID:20848213; http://dx.doi.org/10.1007/s12051-010-0350-9
11. Harris RB, Vouros V, Dorsch K, Fischer P, Wabich M, Bruderlein S, et al. Leptin gene expression in human adipose tissue is switched on by maturation-induced demethylation of specific CpGs in its proximal promoter. J Biol Chem 2006; 281:475420-7; PMID:16836302; http://dx.doi.org/10.1073/pnas.0900191106
12. Fuke T, Yoshizaki T, Kondo M, Morino K, Obata T, Ugi S, et al. Weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568-75; PMID:10456607; http://dx.doi.org/10.1001/jama.282.16.1568
13. Evans SM, Mitchell JA, Shringarpure R, Shank A, Maier H, et al. Enhanced weight loss with pramlintide/metformin: an integrated neuropeptid/obesity approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17:1736-43; PMID:19521351; http://dx.doi.org/10.1038/oby.2009.184
14. Minter-dorfer B, Honwuta JF, DePaoli AM, McCann MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 2011; 60:1474-7; PMID:21411512; http://dx.doi.org/10.2337/db10-1302
15. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996; 93:5579-63; PMID:8650171; http://dx.doi.org/10.1073/pnas.93.12.5793
16. Harris RB, Ramsay TG, Smith SR, Bruch RC. Early and late stimulation of ob mRNA expression in meal-fed and overfed rats. J Clin Invest 1996; 97:2020-4; PMID:8621790; http://dx.doi.org/10.1172/JCI118637
32. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008; 105:10525-30; PMID:18641127; http://dx.doi.org/10.1073/pnas.0801414105

33. Guo KY, Halo P, Leibel RL, Zhang Y. Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol 2004; 287:R112-9; PMID:15001430; http://dx.doi.org/10.1152/ajpregu.00028.2004

34. Zhang Y, Guo KY, Diaz PA, Heo M, Leibel RL. Determinants of leptin gene expression in fat depots of lean mice. Am J Physiol Regul Integr Comp Physiol 2002; 282:R226-34; PMID:11742842

35. Zhang Y, Matheny M, Zolotukhin S, Turner N, Scarpace PJ. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim Biophys Acta 2002; 1584:115-22; PMID:12385894

36. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20:2438-52; PMID:11402339; http://dx.doi.org/10.1038/sj.onc.1204385

37. Frederich RC, Lollmann B, Hamann A, Napolitano-Rosen A, Kahn BB, Lowell BB, et al. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 1995; 96: 1658-63; PMID:7657836; http://dx.doi.org/10.1172/JCI118206

38. Bradley RL, Cheatham B. Regulation of ob gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes. Diabetes 1999; 48:272-8; PMID:10334301; http://dx.doi.org/10.2337/diabetes.48.2.272

39. Buys E, Viengchareun SAY, Bado A, Lombès M. Insulin and glucocorticoids differentially regulate leptin transcription and secretion in brown adipocytes. FASEB J 2001; 15:1357-66; PMID:11387233; http://dx.doi.org/10.1096/fj.00-0669com

40. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Minnicozzi TM, Warden CH, et al. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology 1998; 139: 551-8; PMID:9449624; http://dx.doi.org/10.1210/en.139.2.551

41. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998; 393:684-8; PMID:9641678; http://dx.doi.org/10.1038/31474

42. Considine RV, Corderoy RC, Williams LB, Fawcett RL, Zhang P, Ambrosius WT, et al. Hexosamines regulate leptin production in human subcutaneous adipocytes. J Clin Endocrinol Metab 2000; 85:3551-6; PMID:11061500; http://dx.doi.org/10.1210/jc.85.10.3551

43. Zhang P, Klenk ES, Lazzato MA, Williams LB, Considine RV. Hexosamines regulate leptin production in 3T3-L1 adipocytes through transcriptional mechanisms. Endocrinology 2002; 143:99-106; PMID:11751598; http://dx.doi.org/10.1210/en.143.1.99

44. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97:2152-7; PMID:8621806; http://dx.doi.org/10.1172/JCI118653

45. Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivero DJ, 3rd, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997; 185:171-5; PMID:8996253; http://dx.doi.org/10.1084/jem.185.1.171

46. Wang J, Liu R, Liu L, Chowdhury R, Barzilai N, Tan J, et al. The effect of leptin on Lep expression is tissue-specific and nutritionally regulated. Nat Med 1999; 5:895-9; PMID:10426312; http://dx.doi.org/10.1038/10577

172 Adipocyte Volume 1 Issue 3